+++
INSPIRATION & EXPIRATION
++
The lungs and the chest wall are elastic structures. Normally, no more than a thin layer of fluid is present between the lungs and the chest wall (intrapleural space). The lungs slide easily on the chest wall, but resist being pulled away from it in the same way that two moist pieces of glass slide on each other but resist separation. The pressure in the “space” between the lungs and chest wall (intrapleural pressure) is subatmospheric (Figure 34–7). The lungs are stretched when they expand at birth, and at the end of quiet expiration their tendency to recoil from the chest wall is just balanced by the tendency of the chest wall to recoil in the opposite direction. If the chest wall is opened, the lungs collapse; and if the lungs lose their elasticity, the chest expands and becomes barrel-shaped.
++
++
Inspiration is an active process. The contraction of the inspiratory muscles increases intrathoracic volume. The intrapleural pressure at the base of the lungs, which is normally about –2.5 mm Hg (relative to atmospheric) at the start of inspiration, decreases to about –6 mm Hg. The lungs are pulled into a more expanded position. The pressure in the airway becomes slightly negative, and air flows into the lungs. At the end of inspiration, the lung recoil begins to pull the chest back to the expiratory position, where the recoil pressures of the lungs and chest wall balance (see below). The pressure in the airway becomes slightly positive, and air flows out of the lungs. Expiration during quiet breathing is passive in the sense that no muscles that decrease intrathoracic volume contract. However, some contraction of the inspiratory muscles occurs in the early part of expiration. This contraction exerts a braking action on the recoil forces and slows expiration. Strong inspiratory efforts reduce intrapleural pressure to values as low as –30 mm Hg, producing correspondingly greater degrees of lung inflation. When ventilation is increased, the extent of lung deflation is also increased by active contraction of expiratory muscles that decrease intrathoracic volume.
+++
QUANTITATING RESPIRATORY PHENOMENA
++
Modern spirometers permit direct measurement of gas intake and output. Since gas volumes vary with temperature and pressure and since the amount of water vapor in them varies, these devices have the ability to correct respiratory measurements involving volume to a stated set of standard conditions. It should be noted that correct measurements are highly dependent on the ability for the practitioner to properly encourage the patient to fully utilize the device. Modern techniques for gas analysis make possible rapid, reliable measurements of the composition of gas mixtures and the gas content of body fluids. For example, O2 and CO2 electrodes, small probes sensitive to O2 or CO2, can be inserted into the airway or into blood vessels or tissues and the Po2 and Pco2 recorded continuously. Chronic assessment of oxygenation is carried out noninvasively with a pulse oximeter, which can be easily placed on a fingertip.
+++
Lung Volumes & Capacities
++
Important quantitation of lung function can be gleaned from the displacement of air volume during inspiration and/or expiration. Lung capacities refer to subdivisions that contain two or more volumes. Volumes and capacities recorded on a spirometer from a healthy individual are shown in Figure 34–8. Diagnostic spirometry is used to assess a patient’s lung function for purposes of comparison with a normal population, or with previous measures from the same patient. The amount of air that moves into the lungs with each inspiration (or the amount that moves out with each expiration) during quiet breathing is called the tidal volume (TV). Typical values for TV are on the order of 500–750 mL. The air inspired with a maximal inspiratory effort in excess of the TV is the inspiratory reserve volume (IRV; typically ~2 L). The volume expelled by an active expiratory effort after passive expiration is the expiratory reserve volume (ERV; ~1 L), and the air left in the lungs after a maximal expiratory effort is the residual volume (RV; ~1.3 L). When all four of the above components are taken together, they make up the total lung capacity (~5 L). The total lung capacity can be broken down into alternative capacities that help define functioning lungs. The vital lung capacity (~3.5 L) refers to the maximum amount of air expired from the fully inflated lung, or maximum inspiratory level (this represents TV + IRV + ERV). The inspiratory capacity (~2.5 L) is the maximum amount of air inspired from the end-expiratory level (IRV + TV). The functional residual capacity (FRC; ~2.5 L) represents the volume of the air remaining in the lungs after expiration of a normal breath (RV + ERV).
++
++
Dynamic measurements of lung volumes and capacities have been used to help determine lung dysfunction. The forced vital capacity (FVC), the largest amount of air that can be expired after a maximal inspiratory effort, is frequently measured clinically as an index of pulmonary function. It gives useful information about the strength of the respiratory muscles and other aspects of pulmonary function. The fraction of the vital capacity expired during the first second of a forced expiration is referred to as FEV1 (forced expiratory volume in the first second; Figure 34–9). The FEV1 to FVC ratio (FEV1/FVC) is a useful tool in the recognizing classes of airway disease (Clinical Box 34–2). Other dynamic measurements include the respiratory minute volume (RMV) and the maximal voluntary ventilation (MVV). RMV is normally ~6 L (500 mL/ breath × 12 breaths/min). The MVV is the largest volume of gas that can be moved into and out of the lungs in 1 min by voluntary effort. Typically this is measured over a 15 sec period and prorated to a minute; normal values range from 140 L/min to 180 L/min for healthy adult men. Changes in RMV and MVV in a patient can be indicative of lung dysfunction.
++
+++
COMPLIANCE OF THE LUNGS & CHEST WALL
++
Compliance is developed due to the tendency for tissue to resume its original position after an applied force has been removed. After an expiration during quiet breathing (eg, at the FRC), the lungs have a tendency to collapse and the chest wall has a tendency to expand. The interaction between the recoil of the lungs and recoil of the chest can be measured through a spirometer that has a valve just beyond the mouthpiece. The mouthpiece contains a pressure-measuring device. After the person inhales a given amount, the valve is shut, closing off the airway. The respiratory muscles are then relaxed while the pressure in the airway is recorded. The procedure is repeated after inhaling or actively exhaling various volumes. The curve of airway pressure obtained in this way, plotted against volume, is the pressure-volume curve of the total respiratory system (PTR in Figure 34–10). The pressure is zero at a lung volume that corresponds to the volume of gas in the lungs at FRC (relaxation volume). As can be noted from Figure 34–10, this relaxation pressure is the sum of slightly negative pressure component from the chest wall (Pw) and a slightly positive pressure from the lungs (PL). PTR is positive at greater volumes and negative at smaller volumes. Compliance of the lung and chest wall is measured as the slope of the PTR curve, or, as a change in lung volume per unit change in airway pressure (ΔV/ΔP). It is normally measured in the pressure range where the relaxation pressure curve is steepest, and normal values are ~0.2 L/cm H2O in a healthy adult man. However, compliance depends on lung volume and thus can vary. In an extreme example, an individual with only one lung has approximately half the ΔV for a given ΔP. Compliance is also slightly greater when measured during deflation than when measured during inflation. Consequently, it is more informative to examine the whole pressure-volume curve. The curve is shifted downward and to the right (compliance is decreased) by pulmonary edema and interstitial pulmonary fibrosis (Figure 34–11). Pulmonary fibrosis is a progressive restrictive airway disease in which there is stiffening and scarring of the lung. The curve is shifted upward and to the left (compliance is increased) in emphysema.
++
++
++
CLINICAL BOX 34–2 Altered Airflow in Disease:

Representative lung volume expired over time in normal and diseased lungs during respiratory testing. A) Healthy patient. B) Obstructive disease patient. C) Restrictive disease patient. Note the differences in FEV1, FVC and FEV1/FVC at the bottom of the figure. FEV1, forced expiratory volume in the first second; FVC, forced vital capacity. (Reproduced with permission from Fishman AP: Fishman’s Pulmonary Disease and Disorders, 4th ed. New York, NY: McGraw Hill Medical, 2008.)
Airflow Measurements of Obstructive & Restrictive Disease In the example above, a healthy FVC is ~4.0 L and a healthy FEV1 is ~3.3 L. The calculated FEV1/FVC is ~80%. Patients with obstructive or restrictive diseases can display reduced FVC, on the order of 2.0 L in the example above. Measurement of FEV1, however, tends to vary significantly between the two diseases. In obstructive disorders, patients tend to show a slow, steady slope to the FVC, resulting in a small FEV1, on the order of 1.0 L in the example. However, in the restrictive disorder, patient’s airflow tends to be fast at first, and then quickly level out to approach FVC. The resultant FEV1 is much greater, on the order of 1.8 L in the example, even though FVC is equivalent (compare B, C above). A quick calculation of FEV1/FVC for patients with obstructive (50%) versus restrictive (90%) patterns defines the hallmark measurements in evaluating these two diseases. Obstructive disorders result in a marked decrease in both FVC and FEV1/FVC, whereas restrictive disorders result in a loss of FVC without loss in FEV1/FVC. It should be noted that these examples are idealized and several disorders can show mixed readings.
Obstructive Disease—Asthma Asthma is characterized by episodic or chronic wheezing, cough, and a feeling of tightness in the chest as a result of bronchoconstriction. Although the disease is not fully understood, three airway abnormalities are present: airway obstruction that is at least partially reversible, airway inflammation, and airway hyperresponsiveness to a variety of stimuli. A link to allergy has long been recognized, and plasma IgE levels are often elevated. Proteins released from eosinophils in the inflammatory reaction may damage the airway epithelium and contribute to the hyperresponsiveness. Leukotrienes are released from eosinophils and mast cells, and can enhance bronchoconstriction. Numerous other amines, neuropeptides, chemokines, and interleukins have effects on bronchial smooth muscle or produce inflammation, and they may be involved in asthma.
THERAPEUTIC HIGHLIGHTS Because β2-adrenergic receptors mediate bronchodilation, β2-adrenergic agonists have long been the mainstay of “rescue” treatment for mild to moderate asthma attacks. Inhaled steroids are used even in mild to moderate cases to reduce inflammation; they are very effective, but their side effects can be a problem. Agents that block synthesis of leukotrienes or their CysLT1 receptor have also proved useful in some cases.
++
Airway resistance is defined as the change of pressure (ΔP) from the alveoli to the mouth divided by the change in flow rate
. Because of the structure of the bronchial tree, and thus the pathway for air that contributes to its resistance, it is difficult to apply mathematical estimates of the movement through the bronchial tree. However, measurements where alveolar and intrapleural pressure can be compared to actual pressure (eg, Figure 34–7 middle panel) show the contribution of airway resistance. Airway resistance is significantly increased as lung volume is reduced. Also, bronchi and bronchioles significantly contribute to airway resistance. Thus, contraction of the smooth muscle that lines the bronchial airways will increase airway resistance, and make breathing more difficult.
+++
Role of Surfactant in Alveolar Surface Tension
++
An important factor affecting the compliance of the lungs is the surface tension of the film of fluid that lines the alveoli. The magnitude of this component at various lung volumes can be measured by removing the lungs from the body of an experimental animal and distending them alternately with saline and with air while measuring the intrapulmonary pressure. Because saline reduces the surface tension to nearly zero, the pressure-volume curve obtained with saline measures only the tissue elasticity (Figure 34–12), whereas the curve obtained with air measures both tissue elasticity and surface tension. The difference between the saline and air curves is much smaller when lung volumes are small. Differences are also obvious in the curves generated during inflation and deflation. This difference is termed hysteresis, and notably is not present in the saline generated curves. The alveolar environment, and specifically the secreted factors that help reduce surface tension and keep alveoli from collapsing, contribute to hysteresis.
++
++
The low surface tension when the alveoli are small is due to the presence of surfactant in the fluid lining the alveoli. Surfactant is a mixture of dipalmitoylphosphatidylcholine (DPPC), other lipids, and proteins. If the surface tension is not kept low when the alveoli become smaller during expiration, they collapse in accordance with the law of Laplace. In spherical structures like an alveolus, the distending pressure (P) equals two times the tension (T) divided by the radius (r; P = 2T/r); if T is not reduced as r is reduced, the tension overcomes the distending pressure. Surfactant also helps prevent pulmonary edema. It has been calculated that if it were not present, the unopposed surface tension in the alveoli would produce a 20 mm Hg force; such a force would greatly favor transudation of fluid from the blood into the alveoli.
++
Formation of the phospholipid film is greatly facilitated by the proteins in surfactant. This material contains four unique proteins: surfactant protein (SP)-A, SP-B, SP-C, and SP-D. SP-A is a large glycoprotein and has a collagen-like domain within its structure. It has multiple functions, including regulation of the feedback uptake of surfactant by the type II alveolar epithelial cells that secrete it. SP-B and SP-C are smaller proteins, which are the key protein members of the monomolecular film of surfactant. Like SP-A, SP-D is a glycoprotein. Its full function is uncertain, however it plays an important role in the organization of SP-B and SP-C into the surfactant layer. Both SP-A and SP-D are members of the collectin family of proteins that are involved in innate immunity in the conducting airway as well as in the alveoli. Some clinical aspects of surfactant are discussed in Clinical Box 34–3.
++
Work is performed by the respiratory muscles in stretching the elastic tissues of the chest wall and lungs (elastic work; approximately 65% of the total work), moving inelastic tissues (viscous resistance; 7% of total), and moving air through the respiratory passages (airway resistance; 28% of total). Because the dimensions of pressure × volume (g/cm2 × cm3 = g × cm) has the same dimensions as work (force × distance; g × cm), the work of breathing can be calculated from the previously presented pressure-volume curve (Figure 34–10). Note that the relaxation pressure curve of the total respiratory system (PTR) differs from that of the lungs alone (PL). The amount of elastic work required to inflate the whole respiratory system is less than the amount required to inflate the lungs alone because part of the work comes from elastic energy stored in the thorax.
++
Estimates of the total work of quiet breathing range from 0.3 up to 0.8 kg-m/min. The value rises markedly during exercise, but the energy cost of breathing in normal individuals represents less than 3% of the total energy expenditure during exercise. The work of breathing is greatly increased in diseases such as emphysema, asthma, and heart failure with dyspnea and orthopnea. The respiratory muscles have length-tension relations like those of other skeletal and cardiac muscles, and when they are severely stretched, they contract with less strength. They can also become fatigued and fail (pump failure), leading to inadequate ventilation.
++
CLINICAL BOX 34–3 Surfactant
Surfactant is important at birth. The fetus makes respiratory movements in utero, but the lungs remain collapsed until birth. After birth, the infant makes several strong inspiratory movements and the lungs expand. Surfactant keeps them from collapsing again. Surfactant deficiency is an important cause of infant respiratory distress syndrome (IRDS, also known as hyaline membrane disease), the serious pulmonary disease that develops in infants born before their surfactant system is functional. Surface tension in the lungs of these infants is high, and the alveoli are collapsed in many areas (atelectasis). An additional factor in IRDS is retention of fluid in the lungs. During fetal life, Cl– is secreted with fluid by the pulmonary epithelial cells. At birth, there is a shift to Na+ absorption by these cells via the epithelial Na+ channels (ENaCs), and fluid is absorbed with the Na+. Prolonged immaturity of the ENaCs contributes to the pulmonary abnormalities in IRDS.
Overproduction/dysregulation of surfactant proteins can also lead to respiratory distress and is the cause of pulmonary alveolar proteinosis (PAP).
THERAPEUTIC HIGHLIGHTS Treatment of IRDS is commonly done with surfactant replacement therapy. Interestingly, such surfactant replacement therapy has not been as successful in clinical trials for adults experiencing respiratory distress due to surfactant dysfunction.
+++
DIFFERENCES IN VENTILATION & BLOOD FLOW IN DIFFERENT PARTS OF THE LUNG
++
In the upright position, ventilation per unit lung volume is greater at the base of the lung than at the apex. The reason for this is that at the start of inspiration, intrapleural pressure is less negative at the base than at the apex, and since the intrapulmonary intrapleural pressure difference is less than at the apex, the lung is less expanded. Conversely, at the apex, the lung is more expanded; that is, the percentage of maximum lung volume is greater. Because of the stiffness of the lung, the increase in lung volume per unit increase in pressure is smaller when the lung is initially more expanded, and ventilation is consequently greater at the base. Blood flow is also greater at the base than the apex. The relative change in blood flow from the apex to the base is greater than the relative change in ventilation, so the ventilation/perfusion ratio is low at the base and high at the apex.
++
The ventilation and perfusion differences from the apex to the base of the lung have usually been attributed to gravity: they tend to disappear in the supine position, and the weight of the lung would be expected to create pressure at the base in the upright position. However, the inequalities of ventilation and blood flow in humans were found to persist to a remarkable degree in the weightlessness of space. Therefore, other factors also play a role in producing the inequalities.
+++
DEAD SPACE & UNEVEN VENTILATION
++
Because gaseous exchange in the respiratory system occurs only in the terminal portions of the airways, the gas that occupies the rest of the respiratory system is not available for gas exchange with pulmonary capillary blood. Normally, the volume (in mL) of this anatomic dead space is approximately equal to the body weight in pounds. As an example, in a man who weighs 150 lb (68 kg), only the first 350 mL of the 500 mL inspired with each breath at rest mixes with the air in the alveoli. Conversely, with each expiration, the first 150 mL expired is gas that occupied the dead space, and only the last 350 mL is gas from the alveoli. Consequently, the alveolar ventilation, ie, the amount of air reaching the alveoli per minute, is less than the RMV. Note that because of the dead space, rapid shallow breathing produces much less alveolar ventilation than slow deep breathing at the same RMV (Table 34–1).
++
++
It is important to distinguish between the anatomic dead space (respiratory system volume exclusive of alveoli) and the total (physiologic) dead space (volume of gas not equilibrating with blood; ie, wasted ventilation). In healthy individuals, the two dead spaces are identical and can be estimated by body weight. However, in disease states, no exchange may take place between the gas in some of the alveoli and the blood, and some of the alveoli may be overventilated. The volume of gas in nonperfused alveoli and any volume of air in the alveoli in excess of that necessary to arterialize the blood in the alveolar capillaries is part of the dead space (nonequilibrating) gas volume. The anatomic dead space can be measured by analysis of the single-breath N2 curves (Figure 34–13). From mid-inspiration, the patient takes as deep a breath as possible of pure O2, then exhales steadily while the N2 content of the expired gas is continuously measured. The initial gas exhaled (phase I) is the gas that filled the dead space and that consequently contains no N2. This is followed by a mixture of dead space and alveolar gas (phase II) and then by alveolar gas (phase III). The volume of the dead space is the volume of the gas expired from peak inspiration to the midportion of phase II.
++
++
Phase III of the single-breath N2 curve terminates at the closing volume (CV) and is followed by phase IV, during which the N2 content of the expired gas is increased. The CV is the lung volume above RV at which airways in the lower, dependent parts of the lungs begin to close off because of the lesser transmural pressure in these areas. The gas in the upper portions of the lungs is richer in N2 than the gas in the lower, dependent portions because the alveoli in the upper portions are more distended at the start of the inspiration of O2 and, consequently, the N2 in them is less diluted with O2. It is also worth noting that in most normal individuals, phase III has a slight positive slope even before phase IV is reached. This indicates that even during phase III there is a gradual increase in the proportion of the expired gas coming from the relatively N2-rich upper portions of the lungs.
++
The total dead space can be calculated from the Pco2 of expired air, the Pco2 of arterial blood, and the TV. The tidal volume (VT) times the Pco2 of the expired gas (Peco2) equals the arterial Pco2 (Paco2) times the difference between the TV and the dead space (VD) plus the Pco2 of inspired air (Pico2) times VD (Bohr equation):
++
++
The term Pico2 × VD is so small that it can be ignored and the equation solved for VD, where VD = VT – (Peco2 × VT)/(Paco2)
++
If, for example: Peco2 = 28 mm Hg; Paco2 = 40 mm Hg and VT = 500 mL, then VD = 150 mL
++
The equation can also be used to measure the anatomic dead space if one replaces Paco2 with alveolar Pco2 (Paco2), which is the Pco2 of the last 10 mL of expired gas. Pco2 is an average of gas from different alveoli in proportion to their ventilation regardless of whether they are perfused. This is in contrast to Paco2, which is gas equilibrated only with perfused alveoli, and consequently, in individuals with underperfused alveoli, is greater than Pco2.